RELATIONSHIP OF SERUM ADIPONECTIN AND RESISTIN LEVELS WITH THE SEVERITY OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B
Abstract
Background: Recent research has closely linked adipocytokines to progression of liver inflammation and fibrosis in patients with non-alcoholic liver disease. The aim of this study was to determine the relationship ofserum adiponectin and resistin levels with the severity of liver fibrosis in patients with chronic hepatitis B (CHB), depending on the duration of antiviral therapy.
Methods: The cross-sectional studyincluded75 patients with CHB divided into two groups: T1 group(on antiviral therapy for up to 2 years) and T2 group (on antiviral therapy over 2 years). Control group consisted of 40 healthy persons. Serum concentrations of adiponectin and resistin were estimated with ELISA method, while degree of liver fibrosis was determined using FIB-4and APRIscore.
Results:The higher values of serum resistin concentration were verified in patients with CHBcompared to healthy controls. The mean level of serum resistin concentration was significantly higher in group of patients with higher FIB-4 score (9.12±3.39 vs. 5.58±3.36 ng/mL, p = 0.001), as well as APRI score (17.45 ± 3.96ng/mL vs.4.82 ± 1.11 ng/mL, p = 0.001). Positive correlation was found between serum resistin levels and degree of liver fibrosis (p < 0.001). There was no significant difference between mean serum adiponectin levels according to the values of FIB-4 and APRI scores.
Conclusions:Serum resistin concentration could be a potential noninvasive biomarker of the severity of liver fibrosis in patients with chronic hepatitis B on antiviral therapy.
References
2. Senesi P, LuziL,TerruzziI. Adipokines, myokines, and cardiokines: the role of nutritional interventions. Int J MolSci 2020; 21: 8372. DOI: 10.3390/ijms21218372
3. Chang ML, YangZ,Yang SS.Roles of adipokines in digestive diseases: Markers of inflammation, metabolic alteration and disease progression.Int J MolSci 2020;21 :8308. DOI: 10.3390/ijms21218308
4. AcquaroneE, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: areappraisal.Mech Ageing Dev 2019;178:46-63. DOI: 10.1016/j.mad.2019.01.004
5. Arunkumar EA, Sushil KJ. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J MolSci 2017;18:1321. DOI: 10.3390/ijms18061321
6. Hsu CS , Liu WL, Chao YC, et al. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.HepatolInt 2015; 9:231-42. DOI: 10.1007/s12072-015-9616-2
7. Yalaki S,Yalcin MS. Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years. Niger J ClinPract 2020; 23: 226-31. DOI: 10.4103/njcp.njcp_7_19
8. Koksal AR,Alkim H, Boga S, et al. Effect of entecavir and tenofovirtreatment on noninvasive fibrosis scores: which one is better? Am J Ther2016; 23: e429-38. DOI: 10.1097/MJT.0000000000000203
9. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71:7-33. DOI: 10.3322/caac.21654
10. Jamali R, Hatami N, Kosari F. The Correlation between serum adipokines and liver cell damage in non-alcoholic fatty liver disease. Hepat Mon 2016;16:e37412. DOI: 10.5812/hepatmon.37412
11. Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22: 5096-103. DOI: 10.3748/wjg.v22.i21.5096
12. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol2017; 67: 370-98. DOI: 10.1016/j.jhep.2017.03.021
13. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016;64:773-780. DOI: 10.1016/j.jhep.2015.11.012
14. Lai M, Afdhal NH. Liver fibrosis determination.GastroenterolClin North Am 2019;48:281-9. DOI: 10.1016/j.gtc.2019.02.002
15. Mak LY, Seto WK, Fung J, Yuen MF.Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Rev ClinPharmacol 2019;12: 109-20. DOI: 10.1080/17512433.2019.1567327
16. Durazzo M, Belci P, Niro G, et al. Variations of serum levels of adiponectin and resistin in chronic viral hepatitis. J Endocrinol Invest 2013;36:600-5. DOI: 10.3275/8883
17. Meng Z, Zhang Y,Wei Z, et al.High serum resistin associates with intrahepatic inflammation and necrosis: an index of disease severity for patients with chronic HBV infection. BMC Gastroenterol 2017; 17:6. DOI: 10.1186/s12876-016-0558-5
18. Tsochatzis E,Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-36. DOI: 10.1080/00365520802085387
19. Da Silva TE, Costa-Silva M, Correa CG, et al. Clinical significance of serum adiponectin and resistinlevels in liver cirrhosis. Ann Hepatol 2018;17: 286-99. DOI: 10.5604/01.3001.0010.8659
20. Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in Liver Cirrhosis. Int J MolSci 2017; 18(7):1392. DOI: 10.3390/ijms18071392
21. Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol 2018;10:708-18. DOI: 10.4254/wjh.v10.i10.708
22. Tardelli M, Moreno-Viedma V, Zeyda M, et al. Adiponectin regulates aquaglyceroporin expression in hepatic stellate cells altering their functional state. GastroenterolHepatol 2017;32: 253-60. DOI: 10.1111/jgh.13415
23. You M, Zhou Z, Daniels M, Jogasuria A. Endocrineadiponectin–FGF15/19 axis in ethanol-induced inflammation and alcoholic liver injury. Gene Expr 2018; 18: 103-13. DOI: 10.3727/105221617X15093738210295
Copyright (c) 2021 Nerma Čustović, Senija Rašić
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.